Taken together, the tumour antigens MSLN, CD70, EGFR and HER2 are being exploited as targets for target‐selective CD47 blockade for solid cancer with preclinical proof‐of‐concept for enhanced selectivity and activity. Here, CD47 is linked to neoplasm.